Flagship Ventures' Brian Fiske Named To Forbes' 30 Under 30 List

Flagship Senior Associate Cited for Impact in CRISPR Technology, New Therapeutics and Company Creation

Jan 26, 2016, 11:31 ET from Flagship Ventures

CAMBRIDGE, Mass., Jan. 26, 2016 /PRNewswire/ -- Brian Fiske, senior associate at Flagship Ventures, a venture capital and venture creation firm, has been named to Forbes' "30 Under 30," an elite list of the most influential young people in a variety of high-impact fields.

Forbes cited Dr. Fiske's use of the gene-editing technology CRISPR and his role at KSQ Therapeutics, the precision functional genomic company in which Flagship was a founding investor. Only 13 people were honored for their outstanding achievements in healthcare and therapeutics.

"Brian embodies the spirit of innovation that is central to the work we do at Flagship VentureLabs," said Noubar Afeyan, Ph.D., senior managing partner and CEO of Flagship. "In just a short time, Brian has made substantial contributions at KSQ as well in setting the foundation for other pioneering biotechnology companies."

Fiske, 29, earned his undergraduate degree in biochemical sciences from Harvard, where he also competed on the men's swimming and diving team, and led the team as co-captain in his senior year. He earned a Ph.D. in biology at MIT, where he focused on metabolomics and enzyme biochemistry to discover novel metabolic regulatory mechanisms that enable biomass accumulation in tumors.

Brian is an author on more than 10 scientific papers, and previously worked as a consultant at Bain & Company. He joined Flagship in 2014 after participating in the Flagship VentureLabs Summer Fellows program.

About Flagship Ventures
Flagship develops disruptive innovations that improve the health of people and our planet. Founded in 2000, the firm has launched more than 40 first-in-class companies while investing in another 45. Flagship manages over $1.4 billion in capital and is active in three principal sectors: therapeutics, health technologies, and sustainability. Flagship's current portfolio includes Acceleron (NASDAQ: XLRN), Agios (NASDAQ: AGIO), Seres Therapeutics (NASDAQ: MCRB), T2 Biosystems (NASDAQ: TTOO), as well as several private companies: Editas Medicine, Moderna Therapeutics and Syros Pharmaceuticals. For more information, please visit www.flagshipventures.com.

About Flagship VentureLabs®
Flagship VentureLabs is the innovation foundry of Flagship Ventures. It is the first institution dedicated to entrepreneurial innovation, where discovery, invention and entrepreneuring are performed simultaneously by a world-class team of scientists, innovators and professional entrepreneurs. VentureLabs has used its unique, systematic approach to produce first-in-class companies based on in-house innovations. Since its founding in 2000, the VentureLabs team has founded more than 35 life science companies, including Joule Unlimited, Seres Therapeutics, Pronutria Biosciences, Symbiota and Moderna Therapeutics. For more information, please visit www.flagshipventures.com/venturelabs.

Photo - http://photos.prnewswire.com/prnh/20160126/326003

SOURCE Flagship Ventures